Article | January 11, 2021

Commercializing Disruptive Technologies In Advanced Therapies

Source: Invetech
Future Technology Science

Invetech panel discussion at Phacilitate Advanced Therapies Connect 2020

Our panel discussion at the first virtual Phacilitate Advanced Therapies Connect conference brought together three companies with disruptive technologies in the advanced therapies space.

Comprising of Kevin Alessandri, CEO/CTO, Treefrog Therapeutics, Vincent Ronfard, Chief Innovation Officer, CUTISS, and Rob Schutte, Executive Director, Process Development, Humacyte, the panel shared the journeys of their respective companies – all the way from the back of the napkin to the bedside.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Cell & Gene? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: